Decapitated dolphin in North Carolina prompts $25,000 reward offer from US
The 8-foot-long bottlenose dolphin was found dead on Lea-Hutaff Island, North Carolina, on April 15, according to a statement from the Office of Law Enforcement of the National Oceanic and Atmospheric Administration (NOAA).
The reward notice included a photo of the dolphin, which was missing its head, as it lay on the shore of the remote, undeveloped barrier island, which is north of Wilmington, North Carolina, and only accessible by boat, the agency said.
Officials from the University of North Carolina at Wilmington, which partners with NOAA to respond to dolphin strandings in the region, said that they determined that someone intentionally removed the dolphin's head after it had been stranded on the island.
The agency noted that the dolphin was carrying Brucella, a bacteria that causes the infectious disease brucellosis, which can be transferred to humans through direct contact. Symptoms of the disease include headaches, fever, sweating and generally feeling badly or malaise, according to the Centers for Disease Control and Prevention.
Officials performed a necropsy, an animal autopsy, and the results and cause of death were pending.
Dolphins are not listed as endangered or threatened under the Endangered Species Act, but they are protected under the Marine Mammal Protection Act, which bans harassing, hunting, killing or feeding wild dolphins. Violations can lead to fines up to US$100,000 and up to one year in jail.
Officials said that anyone with information about the Lea-Hutaff Island's dolphin should call the NOAA Enforcement Hotline at (800) 853-1964. People can leave tips anonymously, but to be eligible for the reward, they must include their name and contact information.
The agency has previously offered rewards to the public for information about dolphins that appeared to have been killed. In 2024, it offered up to a US$20,000 reward in exchange for information to find the person who they believe fatally shot a juvenile dolphin at a beach in Louisiana.
And in 2020, federal authorities offered a reward after two dead dolphins were found with gunshot or stab wounds in Florida. NYTIMES
Join ST's Telegram channel and get the latest breaking news delivered to you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
an hour ago
- Business Times
Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push
[PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology to streamline their development. The French drugmaker will pay US$1.15 billion upfront with a commitment for potential milestones worth as much as US$450 million, it said in a statement on Tuesday (Jul 22). Chief executive officer Paul Hudson is looking for innovation that fits with Sanofi's existing offerings, and Vicebio's experimental shots are intended to prevent several respiratory illnesses including RSV, the target of its new therapy Beyfortus. The deal is expected to close in the fourth quarter, and won't have a significant impact on Sanofi's financial guidance for the year, the company said. The transaction helps Sanofi get closer to making next-generation vaccines that offer protection against multiple respiratory viruses in a single shot that isn't mRNA – the technology behind the blockbuster Covid-19 immunisations. Vicebio's technology allows quicker development of liquid combination vaccines that can be stored at fridge temperatures, simplifying manufacturing and distribution by eliminating the need for freezing. The company is working on a single shot against RSV and human metapneumovirus, or hMPV, which is in an exploratory early-stage study. Like several rivals, Sanofi is focusing on cutting-edge therapies while divesting older medicines and its consumer-health division. BLOOMBERG
Business Times
9 hours ago
- Business Times
AstraZeneca vows to spend US$50 billion on US manufacturing, development
[MUNICH/WASHINGTON] AstraZeneca plans to invest US$50 billion in the US before 2030, becoming the latest European pharma company to ratchet up spending in the country ahead of potential tariffs on imported medicines. The investment will go towards manufacturing as well as research and development, Astra said in a statement. It includes US$4 billion for a new facility in Virginia that will make drugs for chronic diseases, Kevin Hassett, director of the US National Economic Council, said on Monday (Jul 21) at an event in Washington, DC. 'With the completion of this investment, substantially all of AstraZeneca's pharmaceuticals sold at the United States will be produced in the United States,' Hassett said. Astra's announcement comes as European drug companies rush to highlight their significant footprints in the US in hopes of mitigating the impact of any potential tariffs from US President Donald Trump. Astra already announced plans in November, a week after Trump's election, to invest US$3.5 billion in the US by the end of 2026, noting at the time that it employs nearly 18,000 people in the country. Since then, European competitors have touted even larger spending plans. Switzerland's Novartis in April announced plans for US$23 billion in US-based infrastructure spending, while cross-town rival Roche Holding said it would invest US$50 billion. In May, French drugmaker Sanofi announced intent to invest at least US$20 billion in the US by 2030. Pascal Soriot, who's been chief executive officer of Astra since 2012, has also urged tariff restraint. This spring, he recommended that US officials exempt medicines from tariffs, arguing that tax incentives are a better way to attract investment in drug development and manufacturing. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Trump has proposed various timelines for tariffs on pharmaceuticals, most recently floating duties that would be imposed as soon as Aug 1. The president said that he expects to give companies a year to bring manufacturing to the US before imposing tariffs as high as 200 per cent. Meanwhile, Soriot has raised concerns in the UK about his commitment to the home country. He has long complained about the UK's regulatory environment, which he says is a threat to hold back the UK from staying competitive with the US and China. In January, Astra abandoned plans for a £450 million (S$777 million) vaccine manufacturing plant in Liverpool. The company operates 17 manufacturing sites in 12 US states. Earlier this month, British paper The Times reported that Soriot is considering moving the company's stock listing to the US. That would be a major blow to the UK's equity markets, which have endured similar defections from other companies in recent years. Under Soriot's leadership, Astra's market value has more than tripled as the company has become a global powerhouse in cancer medicines. It's also built up a significant drug pipeline for other areas including cardiovascular, renal and metabolic diseases. BLOOMBERG
Straits Times
a day ago
- Straits Times
Trial of new dengue vaccine begins recruitment for child participants in Singapore
Find out what's new on ST website and app. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying (left), and Dr Zhong Youjia, another investigator on the study. SINGAPORE – A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine in children aged two to 17. Developed by US-based pharmaceutical firm MSD, V181 is a single-dose vaccine that aims to provide protection against all four serotypes, or strains, of the dengue virus. Phase three clinical trials are typically the last stage of testing before a drug's details and clinical trial results are submitted to the regulatory authorities for approval. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying, noted that V181 is a live-attenuated vaccine, which uses weakened versions of all four dengue serotypes. 'Using the weakened forms of all these four dengue serotypes stimulates a human immune response to create protection against dengue infection in future,' said Prof Chia, who also heads the National Centre for Infectious Diseases Research Office. The new study here hopes to recruit at least 700 healthy children between the ages of two and 17, including both those who have previously contracted dengue and those who have never had the disease, said Dr Zhong Youjia, another investigator on the study. This particular study focuses on children as they are more vulnerable to dengue and are also at a greater risk of severe infection, said the associate consultant at National University Hospital's (NUH) Khoo Teck Puat – National University Children's Medical Institute. Side effects from the vaccine have been mild and short-lived, said Prof Chia, noting that they include muscle aches and fatigue. Children enrolled in the study will be randomly chosen to get a single shot of either the vaccine or a placebo. 'There have been no serious adverse events linked to vaccination with V181 to date, and the previous trials actually have shown a very good and favourable safety profile,' Prof Chia said. In Singapore, the study is being conducted at NUH and Tan Tock Seng Hospital, which have already started recruiting participants. Only a handful of children have been recruited so far for the study here, which began in June, said Dr Zhong. A third recruitment site, KK Women's and Children's Hospital, is also in the works. As at July 12, there have been 2,816 dengue cases recorded here in 2025, according to figures from the National Environment Agency (NEA). In May, NEA noted that the number of dengue cases recorded here between January and May 2025 has dropped by about 74 per cent from the same period in 2024. Worldwide, the study aims to enrol about 12,000 healthy children, also between the ages of two and 17, who will receive either a single dose of V181 or a placebo. It aims to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific, including Indonesia, Malaysia and the Philippines. Developing effective dengue vaccines has been difficult as the four serotypes are effectively four different viruses, said Prof Chia. While getting infected by one serotype grants lifelong protection against that particular strain, it provides only short-term protection against the other three, she said. This short-term protection eventually wanes, she noted, adding that those who contract dengue more than once risk antibody-dependent enhancement – a phenomenon where antibodies that are generated due to a vaccine or prior infection actually increase the severity of an infection. Dr Zhong noted this can result in dengue shock syndrome, otherwise known as dengue haemorrhagic fever, a potentially life-threatening complication with symptoms including circulatory failure. Designing a dengue vaccine has been challenging as it has to take into account this phenomenon, Prof Chia said. Should the trials be successful and the vaccine meet regulatory requirements, V181 could be commercially available as early as within the next three to five years, said Dr Zhong. Dr Paula Annunziato, senior vice-president for infectious diseases and vaccines global clinical development at MSD Research Laboratories, noted that half the world's population live in areas at risk for dengue. 'If successful, V181 could provide an important single-dose option for at-risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe,' she said. Dengvaxia, developed by Sanofi Pasteur, is currently the only dengue vaccine approved for use in Singapore. However, it is available only for those between 12 and 45 years old who have previously been infected and poses an increased risk of causing severe dengue in those who have never been infected. In May 2024, another quadrivalent vaccine, Qdenga, received pre-qualification from the World Health Organisation (WHO) – a process that aims to ensure the safety and efficacy of treatments – with WHO recommending the vaccine's use for children aged between six and 16 in dengue-prone areas. Developed by Japanese pharmaceutical company Takeda, Qdenga was made available in Malaysia in June 2024 . Qdenga was submitted for approval here in 2022. However, the following year, the Health Sciences Authority said Takeda had withdrawn its application. The authority said then that the company could submit another application with further clinical data on the vaccine meeting the 'required safety, efficacy and quality standards for use locally'.
